AICAR vs Tirzepatide
A side-by-side research comparison of AICAR and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AICAR | Tirzepatide |
|---|---|---|
| Full name | AICAR (AMPK Activator / Exercise Mimetic) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound | FDA Approved |
| Mechanism | AICAR is converted intracellularly to ZMP, which mimics AMP and directly activates AMP-activated protein kinase (AMPK). AMPK activation shifts metabolism toward fat burning, mitochondrial biogenesis, and glucose uptake, mimicking effects of endurance exercise. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 258.23 Da | 4,814 Da |
| Half-life | Short | 5 days (120 hours) |
| Bioavailability | Injection (research); poor oral | High (SubQ ~80%) |
| Typical dose | Not established for humans | 2.5 mg → titrate up to 15 mg |
| Frequency | Research only | Once weekly |
| Route | Injection (research) | Subcutaneous injection |
AICAR reported benefits
- AMPK activation (exercise-mimetic)
- Increased fat oxidation
- Mitochondrial biogenesis
- Improved endurance (animal models)
- Enhanced glucose uptake
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.